Chemical arthrodesis of the distal tarsal joints using sodium monoiodoacetate in 104 horses.

This retrospective study of 104 horses with arthritis of the lower hock joints tested whether injecting sodium monoiodoacetate (a cartilage-destroying drug) could safely fuse the painful joints and relieve lameness. Most horses that were followed became sound by 12–24 months, with complication rates low and outcomes comparable to surgical fusion.

What problem was studied and why it matters

• Degenerative joint disease (DJD) of the distal intertarsal (DIT) and tarsometatarsal (TMT) joints (“lower hock joints”) is a common cause of hindlimb lameness in horses.
• When medical management fails, the goal shifts to arthrodesis (joint fusion), which eliminates motion and pain in these low-motion joints.
• Surgical arthrodesis can be effective but requires specialized equipment, anesthesia, and carries cost and risk; a chemical method that can be done standing with minimal equipment would be valuable.
• Sodium monoiodoacetate (MIA) is a chondrolytic agent that kills cartilage cells, promoting eventual bony ankylosis; the study evaluates its clinical effectiveness and safety for chemical arthrodesis.

Study design and population

• Design: Retrospective clinical study of 104 client-owned horses.
• Diagnosis: DJD of one or more DIT and/or TMT joints based on history, lameness exam, radiographs, and, in some cases, response to intra-articular anesthesia or medication.
• Setting: Sedated, standing horses treated in a clinical setting.

Intervention and technique

• Procedure: Intra-articular injection of sodium monoiodoacetate (MIA) into affected distal tarsal joints using 23-gauge needles in standing, sedated horses.
• Dose: Mean intra-articular dose 192 mg per treated joint (exact volumes/concentrations adjusted to minimize risk).
• Needle placement verification: Positive contrast arthrography of the DIT joint performed in all horses to confirm correct intra-articular placement and assess for unintended communication with other synovial structures (a key safety step to prevent extra-articular spread).
• Rehabilitation: Graded exercise program started 7–10 days post-injection.

Outcome measures and follow-up schedule

• Clinical outcome: Lameness/soundness assessment at approximately 3, 6, 12, and 24 months after treatment.
• Imaging outcome: Radiographic evidence of ankylosis (fusion) of treated joints at the same time points.
• Follow-up: Where possible, horses were re-examined at each interval; not all horses were available at every time point (attrition over time).

Key results

• Soundness (number sound/number examined):
  • 3 months: 0/57 (0%).
  • 6 months: 14/55 (25.5%).
  • 12 months: 41/50 (82%).
  • 24 months: 29/34 (85.3%).
• Radiographic ankylosis (number with fusion/number radiographed):
  • 3 months: 5/55 (9.1%).
  • 6 months: 24/38 (63.2%).
  • 12 months: 26/30 (86.7%).
  • 24 months: 18/18 (100%).
• Adverse effects:
  • Marked post-injection pain: 6.7% of horses.
  • Significant complications requiring further treatment: 3.8% of horses.

Interpretation of findings

• Time course matters: Clinical improvement and radiographic fusion were uncommon at 3 months but rose sharply by 6–12 months, consistent with a gradual fusion process after chondrolysis.
• Concordance of outcomes: By 12–24 months, most evaluated horses were both radiographically fused and clinically sound, indicating that chemical arthrodesis can meet the therapeutic goal of pain relief via joint fusion.
• Clinical relevance: The high proportion of sound horses at 12–24 months suggests this technique can restore function for many horses with distal tarsal DJD.

Safety profile and risk mitigation

• Overall, adverse events were infrequent; however, a small subset experienced marked post-injection pain or complications requiring additional care.
• Risk control measures emphasized by the authors:
  • Meticulous needle placement confirmed by contrast arthrography to avoid inadvertent injection into unintended synovial spaces.
  • Use of appropriate injection volume and concentration to minimize extra-articular leakage and tissue irritation.
  • Performing the procedure in standing, sedated horses reduced anesthesia-related risks.

Comparison with surgical arthrodesis

• Effectiveness: Authors report outcomes comparable to surgical arthrodesis, which typically aims for similar soundness rates once fusion is achieved.
• Practical advantages: Chemical arthrodesis uses minimal equipment, can be done standing, and may reduce cost and perioperative risk relative to surgery.
• Timeline: As with surgical approaches, meaningful improvement often requires months as ankylosis develops.

Strengths and limitations

• Strengths:
  • Large case series (104 horses) for a specific, practical intervention.
  • Systematic verification of joint access with contrast arthrography enhances internal validity and safety.
  • Multiple follow-up time points with both clinical and radiographic endpoints.
• Limitations:
  • Retrospective design without a randomized control group limits causal inference and direct comparison to alternative treatments.
  • Attrition over time (fewer horses at later checkpoints) may introduce follow-up bias.
  • Details on case selection, concurrent therapies, and standardized lameness scoring are not fully described in the abstract.

Clinical takeaways

• Candidates: Horses with DJD confined to the DIT and/or TMT joints that have failed medical management are potential candidates for chemical arthrodesis.
• Owner expectations: Improvement is typically delayed; the majority of benefits appear between 6 and 12 months as fusion progresses.
• Procedure considerations: Accurate intra-articular placement and careful dosing are crucial to efficacy and safety; using contrast arthrography to verify placement is advisable.
• Rehabilitation: A structured, graded exercise program starting about a week after injection is part of the protocol.

Bottom line

• Chemical arthrodesis with sodium monoiodoacetate, performed in the standing horse with verification of needle placement, can effectively fuse distal tarsal joints and return many horses to soundness within 12–24 months, with low rates of significant complications.